In our comprehensive study in MLL-fused AML/ALL models, we have used inhibitors against CDK9 (BAY 1251152), DOT1L (EPZ-5676), BRD2/3/4 (OTX015), MENIN-MLL interaction (BAY-155), and DHODH (Brequinar). Here, KMT2A is linked to acute lymphoblastic leukemia.